Micronbrane Medical

Micronbrane Medical is a Taiwan-based, woman-led life science company focused on innovative solutions for metagenomic next-generation sequencing (mNGS). The company aims to improve pathogen detection and microbial analysis, addressing challenges in mNGS with technologies that enhance sensitivity, reduce costs, and accelerate results. Their goal is to advance infectious disease diagnostics and microbiological research on a global scale. The company’s core offerings include the PaRTI-Seq™ technology, which combines host DNA depletion, mNGS-qualified reagents, and advanced bioinformatics for fast and accurate pathogen detection from clinical samples. They also provide a specialized bioinformatics pipeline, PaRTI-Seq Analysis, which processes sequencing data securely and delivers actionable insights. Additionally, Micronbrane Medical offers metagenomic collection devices and reagents that improve microbial read accuracy and reduce turnaround times. Micronbrane Medical serves healthcare providers, academic researchers, and laboratories worldwide, enabling efficient pathogen detection from various sample types. With a small team and funding under $5 million, the company is committed to making rapid and comprehensive pathogen detection accessible globally. Dr. Mengchu Wu leads the company, emphasizing innovation and strategic partnerships.

• Employees 16
• Founded 2020
• Annual Revenue $1000000
• Total Funding $4500000